Research programme: microbial compounds - Biosortia Pharmaceuticals
Latest Information Update: 28 Jul 2020
At a glance
- Originator Biosortia Pharmaceuticals
- Developer Biosortia Pharmaceuticals; Nationwide Children's Hospital; The Ohio State University Comprehensive Cancer Center
- Class Small molecules
- Mechanism of Action Immunostimulants; Interleukin 17 modulators; PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis; Cancer; Hypercholesterolaemia; Liver cancer; Neuroblastoma; Psoriasis; Seizures
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Arthritis in USA
- 28 Jul 2020 No recent reports of development identified for research development in Hypercholesterolaemia in USA
- 28 Jul 2020 No recent reports of development identified for research development in Psoriasis in USA